Rapid Micro Biosystems to Present at the H.C. Wainwright 27th Annual Global Investment Conference
Rapid Micro Biosystems (NASDAQ:RPID), a life sciences technology company specializing in automation solutions for healthcare product manufacturing, announced its participation in the H.C. Wainwright 27th Annual Global Investment Conference.
The presentation is scheduled for Tuesday, September 9, 2025, at 11:00 a.m. ET in New York. Investors can access the live webcast through the company's investor relations website at investors.rapidmicrobio.com, with a replay available after the event.
Rapid Micro Biosystems (NASDAQ:RPID), azienda di tecnologie per le scienze della vita specializzata in soluzioni di automazione per la produzione di prodotti sanitari, ha annunciato la sua partecipazione al H.C. Wainwright 27th Annual Global Investment Conference.
La presentazione è prevista per martedì 9 settembre 2025 alle 11:00 ET a New York. Gli investitori potranno seguire la diretta streaming tramite il sito delle relazioni con gli investitori della società all'indirizzo investors.rapidmicrobio.com; la registrazione sarà disponibile in replay dopo l'evento.
Rapid Micro Biosystems (NASDAQ:RPID), una empresa de tecnología en ciencias de la vida especializada en soluciones de automatización para la fabricación de productos sanitarios, anunció su participación en la H.C. Wainwright 27th Annual Global Investment Conference.
La presentación está programada para el martes 9 de septiembre de 2025 a las 11:00 a. m. ET en Nueva York. Los inversores podrán acceder a la transmisión en vivo a través del sitio web de relaciones con inversores de la compañía en investors.rapidmicrobio.com; habrá una repetición disponible después del evento.
Rapid Micro Biosystems (NASDAQ:RPID), 의료 제품 제조를 위한 자동화 솔루션을 전문으로 하는 생명과학 기술 기업이 H.C. Wainwright 27th Annual Global Investment Conference에 참가한다고 발표했습니다.
발표는 2025년 9월 9일 화요일 동부표준시(ET) 오전 11시 뉴욕에서 예정되어 있습니다. 투자자들은 회사 투자자관계 웹사이트 investors.rapidmicrobio.com을 통해 라이브 웹캐스트를 시청할 수 있으며, 행사 후 다시보기(replay)도 제공됩니다.
Rapid Micro Biosystems (NASDAQ:RPID), une société de technologie des sciences de la vie spécialisée dans les solutions d'automatisation pour la fabrication de produits de santé, a annoncé sa participation à la H.C. Wainwright 27th Annual Global Investment Conference.
La présentation est prévue le mardi 9 septembre 2025 à 11h00 (heure de l'Est) à New York. Les investisseurs pourront suivre la diffusion en direct via le site des relations investisseurs de la société à investors.rapidmicrobio.com ; un replay sera disponible après l'événement.
Rapid Micro Biosystems (NASDAQ:RPID), ein Unternehmen der Life-Sciences-Technologie, das sich auf Automatisierungslösungen für die Herstellung von Gesundheitsprodukten spezialisiert hat, gab seine Teilnahme an der H.C. Wainwright 27th Annual Global Investment Conference bekannt.
Die Präsentation ist geplant für Dienstag, 9. September 2025, um 11:00 Uhr ET in New York. Investoren können das Live-Webcast über die Investor-Relations-Website des Unternehmens unter investors.rapidmicrobio.com verfolgen; ein Replay wird nach der Veranstaltung verfügbar sein.
- None.
- None.
LEXINGTON, Mass., Sept. 02, 2025 (GLOBE NEWSWIRE) -- Rapid Micro Biosystems, Inc. (Nasdaq: RPID) (the “Company”), an innovative life sciences technology company providing mission critical automation solutions to facilitate the efficient manufacturing and fast, safe release of healthcare products, today announced that the Company will present at the H.C.Wainwright 27th Annual Global Investment Conference in New York, NY.
The Company is scheduled to present on Tuesday, September 9, 2025, at 11:00 a.m. ET. A live webcast of the presentation will be available on the Rapid Micro Biosystems investor relations website at https://investors.rapidmicrobio.com/ and can be accessed here. The webcast will be archived and available for replay after the event.
About Rapid Micro Biosystems
Rapid Micro Biosystems is an innovative life sciences technology company providing mission critical automation solutions to facilitate the efficient manufacturing and fast, safe release of healthcare products such as biologics, vaccines, cell and gene therapies, and sterile injectables. The Company’s flagship Growth Direct system automates and modernizes the antiquated, manual microbial quality control (“MQC”) testing workflows used in the largest and most complex pharmaceutical manufacturing operations across the globe. The Growth Direct system brings the quality control lab to the manufacturing floor, unlocking the power of MQC automation to deliver the faster results, greater accuracy, increased operational efficiency, better compliance with data integrity regulations, and quicker decision making that customers rely on to ensure safe and consistent supply of important healthcare products. The Company is headquartered Lexington, Massachusetts and has U.S. manufacturing in Lowell, Massachusetts, with global locations in Switzerland, Germany, and the Netherlands. For more information, please visit www.rapidmicrobio.com or follow the Company on X (formerly known as Twitter) at @rapidmicrobio or on LinkedIn.
Investor Contact: Michael Beaulieu, CFA Vice President, Investor Relations and Corporate Communications mbeaulieu@rapidmicrobio.com Media Contact: media@rapidmicrobio.com
FAQ
When is Rapid Micro Biosystems (RPID) presenting at the H.C. Wainwright Conference?
How can investors watch the Rapid Micro Biosystems (RPID) H.C. Wainwright presentation?
What does Rapid Micro Biosystems (RPID) do?
Where is the H.C. Wainwright Conference with RPID being held?
